Jiangsu Hengrui Pharmaceuticals announced that the ANDA for paclitaxel injection submitted to the FDA has been approved, making it the first manufacturer to obtain approval for this generic drug variety in the United States. The global sales of paclitaxel for injection in 2023 are approximately 2.597 billion US dollars, with the company having accumulated research and development expenses of about 52.91 million yuan for related projects.
恒瑞医药：注射用紫杉醇获美国FDA批准
Jiangsu Hengrui Pharmaceuticals: Paclitaxel for injection approved by the FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated